PrimeRFP SCOUT · Federal Contract Recompete Brief

HT942525CE039PHASE 1 placebo-controlled dose-escalation — Inhalon Biopharma, Inc

Inhalon Biopharma, Inc holds $5.4M across 2 federal awards, concentrated at Department of Defense (DOD). This PIID sits alongside 1 related award in the incumbent pipeline. Competition previously drew 44 offers. Set-aside status: NONE. Recompete timing centers on the Dec 31, 2027 PoP end — agencies typically plan 12–18 months ahead.

Army Med Res Acq Activity
Awarding office
Inhalon Biopharma, Inc
Recipient
Dec 31, 2027
PoP end
$3.2M
Obligated
$3.2M
Potential
541715
NAICS
AN13
PSC
NONE
Set-aside
44 bidders on last award

Watch this recompete

One email. No account. We ping you if the window moves.

Score my position vs Inhalon Biopharma, Inc — $90

Contract facts

NONE
Contract numberHT942525CE039
AgencyArmy Med Res Acq Activity
Awarding officeArmy Med Res Acq Activity
Awarding agencyDepartment of Defense (DOD)
Funding agencyDepartment of Defense (DOD)
IncumbentInhalon Biopharma, Inc
CAGE87U21
UEIHFQSJ2GMNRU6
NAICS541715
PSCAN13
Place of performanceMORRISVILLE NC
Pricing typeFixed Price Level Of Effort
Extent competedFull And Open Competition
Related solicitationHT942524SJWMR
PoP startSep 22, 2025
PoP end (current)Dec 31, 2027
Obligated$3.2M
Current value$3.2M
Potential value$3.2M

A PHASE 1 PLACEBO-CONTROLLED DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF IN-007, A NEBULIZED, PAN-SARS ACE2-DECOY THERAPEUTIC FOR PANDEMIC PREPAREDNESS is a federal NONE award for Army Med Res Acq Activity held by Inhalon Biopharma, Inc. Estimated value $3.2M ($3.2M obligated). Current period of performance ends Dec 31, 2027. Last award drew 44 bidders. Place of performance: MORRISVILLE NC. Related solicitation HT942524SJWMR.

A PHASE 1 PLACEBO-CONTROLLED DOSE-ESCALATION SAFETY AND PHARMACOKINETIC STUDY OF IN-007, A NEBULIZED, PAN-SARS ACE2-DECOY THERAPEUTIC FOR PANDEMIC PREPAREDNESS

Recompete timing

Public
Expiring in 480 days

Current PoP ends Dec 31, 2027 (480 days remaining). Agencies typically plan 12–18 months ahead — position before the PoP clock runs out.

Incumbent footprint

Public record

Inhalon Biopharma, Inc$5.4M obligated across 2 awards (firm-wide, all agencies).

Sole agency: Department of Defense (DOD)
Department of Defense (DOD)$5.4M · 100% of firm total
Open full company profile

Related awards

Same incumbent
HT942524C0076
DEVELOPING IN-007 AS A WIDELY DEPLOYABLE INHALED TREATMENT AGAINST PATHOGENS UTILIZING HUM…
$2.2M
Dec 22, 2026

Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP

More in SCOUT
Size up the competition →Research the incumbent →

Frequently asked questions

What is contract HT942525CE039?

HT942525CE039 (PHASE 1 placebo-controlled dose-escalation) is a Army Med Res Acq Activity award with a potential value of $3.2M, currently held by Inhalon Biopharma, Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.

Which office awarded HT942525CE039?

Army Med Res Acq Activity awarded HT942525CE039 to Inhalon Biopharma, Inc (potential $3.2M).

Who is the incumbent on HT942525CE039?

Inhalon Biopharma, Inc is the incumbent with $5.4M across 2 related awards in SCOUT’s public footprint. The current period of performance ends Dec 31, 2027.

When does Inhalon Biopharma, Inc’s HT942525CE039 come up for recompete?

SCOUT tracks a period-of-performance end of Dec 31, 2027. Actual solicitation timing can shift with extensions, bridges, or consolidations.

Seen enough? Run one full capture cycle on HT942525CE039 — $90 for 90 days.

This page stays free. Pilot is the live layer: displacement scoring, recompete pipeline, Daily Brief, and SCOUT MCP for 90 days. If you already live in Claude or ChatGPT and only need live search, start MCP Explorer at $29/mo.

Start Pilot — $90

$1/day · one payment · no subscription

Use SCOUT in your AI client — $29/mo

Classify + search inside Claude, ChatGPT, Cursor

Compare plans

Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.

Data as of · refreshed monthlyLatest procurement action
Sources: USASpending, FPDS, SAM.gov · Public-record facts + SCOUT analysis shown above; personalized scoring in SCOUT.
primerfp.com/intel/contract/HT942525CE039